Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia

This study is a single-arm, open-label, dose-escalating trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of anti human CI-135 (FLT3) CAR-T Injection , and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory Acute Myeloid Leukemia.

Trial Details

NCT ID
NCT06760260
Phase
EARLY_PHASE1
Sponsor
Hrain Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Human Derived anti-CI135 CAR-T Injection
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Subjects must meet all of the following criteria to be enrolled:
  • Subjects volunteer to participate in clinical trails, understand and inform the trials and sign informed consent form, be willing to complete all t…
  • Aged from 18 to 70 years (including cut-off value), Male and female;
  • Expected survival \> 12 weeks;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →